Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
107.18
(
1.98%
)
Bitcoin
68,271.30
(
-0.90%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 229853

Tuesday, 03/31/2020 11:37:05 AM

Tuesday, March 31, 2020 11:37:05 AM

Post# of 257269
BMY/BLUE submit BLA for bb2121 (anti-BCMA CAR-T):

https://finance.yahoo.com/news/bristol-myers-squibb-bluebird-bio-105900728.html

bb2121 is one of the three drugs that comprise the $9/sh BMY-R CVR (#msg-145844551); it has an FDA-approval deadline of 3/31/21, which is doable if there is no hitch in the FDA review.

The Zeposia (ozanimod) FDA approval has already occurred (#msg-154586608), which leaves liso-cel/JCAR017 as the only other requirement; liso-cel has a PDUFA date of 8/17/20 and a CVR deadline of 12/31/20.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today